EU opens antitrust investigation into Vifor Pharma for trashing rival Pharmacosmos
The EU Commission is concerned that Vifor Pharma might have abused a ”dominant position” by spreading false safety information about its closest European competitor on the IV iron treatment market, Pharmacosmos.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Monofer, an iron deficiency drug developed by Pharmacosmos, might have faced unfair conditions on the European market for years due to possible disparaging attempts by Vifor Pharma, according to the EU Commission, whose concerns have now led to a formal antitrust investigation into the matter.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos settles legal dispute with Vifor
For subscribers
.jpg&w=384&q=75)
